Document clinical contraindication to semaglutide: Persistent nausea or vomiting preventing dose escalation beyond initial doses, a documented thyroid concern (e.g., personal or family history of MEN 2 or medullary thyroid carcinoma), or another clinically documented intolerance can serve as the basis for the exception request
Structurally, the product was optimized on the basis of exenatide, and the glycine 2, methionine 14 and asparagine 28 positions were modified to improve enzyme stability and chemical stability based on the polypeptide backbone
For abdominal injections, some products recommend gently pinching a fold of skin between the thumb and forefinger to ensure subcutaneous placement, while others (particularly auto-injectors) may not require this step
A well-established part of how they work is slowing gastric emptying, so food stays in the stomach longer, and this is documented in the FDA prescribing information for these drugs
When medically appropriate, we prescribe GLP-1s for conditions like cardiac and vascular disease, sleep apnea, kidney disease, type 2 diabetes and stroke risk
Cardiologists treating patients with atherosclerotic cardiovascular disease are increasingly initiating semaglutide as a cardiovascular risk modifier, adding an estimated 4.8 million new commercial GLP-1 patients annually
